

CURRICULUM VITAE

Date: October 21, 2014

I. PERSONAL

Name: Mark Schoenberg, M.D.

Office Phone: (718) 920-7606

Office Fax: (718) 547-2902

Current Academic Rank: Professor and Chairman, Department of Urology
Montefiore Medical Center/Albert Einstein College of Medicine

Primary Department: Urology

Citizenship: U.S. Citizen

II. HIGHER EDUCATION

Yale University New Haven, Connecticut	B.A.	1980
---	------	------

University of Texas School of Medicine Houston, TX	M.D.	1986
--	------	------

III. LICENSURE AND CERTIFICATION

FLEX Examination Pittsburgh, Pennsylvania Passed, December		1986
--	--	------

American Board of Urology Part I Passed, June		1992
---	--	------

American Board of Urology Part II Passed, February		1996
--	--	------

American Board of Urology Recertified Diplomat, February		2005
---	--	------

IV. HONORS

Bachelor of Arts <i>Cum laude</i> Yale University	1980
Alpha Omega Alpha University of Texas	1986
Pfizer Scholar	1998
V. <u>SOCIETIES AND MEMBERSHIPS</u>	
American Association of Cancer Research	1994-Present
American Urological Association	1994-Present
Mid-Atlantic Section/A.U.A.	1995-2014
Bladder Health Council/A.F.U.D.	1996-2000
New York Section/A.U.A.	2014-Present
Maryland Urological Society Medical and Chirurgical Faculty of Maryland	1996-2014
Fellow, American College of Surgeons	1997-Present
Society of Urologic Oncology	1999-Present
Nominating Committee Mid-Atlantic Section A.U. Mark P. Schoenberg, M.D.	2000-2001
Chairperson, Scientific Advisory Board The Bladder Cancer Advocacy Network	2006-2008
VI. <u>UNIVERSITY SERVICE</u>	
Medical Staff Conference Committee Johns Hopkins Health System	1995-2001
CapCure Prize Committee for Prostate Cancer Research	1997-1999
Johns Hopkins Hospital Cancer Committee	1998-1999

Young Urologists Committee for the American Urological Association	2001-2002
Committee on Faculty Development and Gender	2003-2006
JHH International Services Medical Director for the Anadoulu Medical Center Istanbul, Turkey	2004-2006
CPA Board of Governors/JHMI	2006-2009
CPA Contracting Committee, JHMI	2007-2014
VII. <u>EDITORIAL EXPERIENCE</u>	
Urology Editorial Board	1998-1999
Urology Associate Editor	1999-2009
<i>Seminars in Urologic Oncology</i> Senior Editor	2003 - 2013
<i>Journal of Urology</i> Assistant Editor	2004 – 2008
Ad Hoc Reviewer: <i>Journal of Urology</i> <i>Journal of the National Cancer Institute</i> <i>Cancer Research</i> <i>Cancer</i> <i>Clinical Cancer Research</i> <i>NEJM</i> <i>European Urology</i> <i>Cancer</i> Ad Hoc Reviewer	
VIII. <u>RESEARCH & PROFESSIONAL EXPERIENCE</u>	
GI peptide biochemistry Department of Surgery UTMB-Galveston, TX	1980-81

GnRH release in subhuman primates Andrology Section Sir Charles, Giardner Hospital Perth, Western Australia	1981
Interferons in human cancer Section of Clinical Immunology M.D. Anderson Hospital Houston, Texas	1981-82
Post-graduate General Surgery Training University of Pennsylvania Philadelphia, Pennsylvania	1986-88
<i>Assistant Instructor</i> , Urology Philadelphia, Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania	1988-92
<i>Chief Resident</i> , Department of Urology University of Pennsylvania Philadelphia, Pennsylvania	1991-92
<i>Fellow</i> , Brady Urological Institute The Johns Hopkins Hospital Baltimore, Maryland	1992-94
<i>Assistant Professor</i> , Department of Urology Johns Hopkins Hospital Baltimore, Maryland	1994-98
<i>Assistant Professor of Oncology</i> The Johns Hopkins Oncology Center Baltimore, Maryland	1995
<i>Associate Professor of Urology and Oncology</i> The Johns Hopkins Hospital Baltimore, Maryland	1998-2002
<i>Director of Urologic Oncology</i> Departments of Urology and Oncology The Johns Hopkins University School of Medicine Baltimore, Maryland	1998-2014

Bernard L. Schwartz 2005- 2014
Distinguished Professor of Urologic Oncology
 The Johns Hopkins Hospital
 Baltimore, Maryland

Professor and Chairman 2014 - Present
 The Department of Urology
 Montefiore Medical Center/
 Albert Einstein College of Medicine

IX. GRANTS/CONTRACTS

1. Physician Research Training Grant, American Cancer Society, 1992-1994. Fellowship Director: ER Barrack, Ph.D. Brady Urological Institute, Johns Hopkins University School of Medicine: Androgen receptor molecular biology in prostate cancer.
2. Clinical Oncology Career Development Award, American Cancer Society, 1996-1999. Transitional cell carcinoma: Molecular predictors of clinical outcome.
3. Small Business Innovation Research Program, RPN #96-11-27-01, OncorMed, Inc., 1996. Principal Investigator: CL Carter, Ph.D., M.P.H., Co-Investigators: M. Bywater, M.D., Ph.D.
4. **MP Schoenberg, M.D.**, C. Enger, M.S., Ph.D. Early detection of bladder cancer by microsatellite analysis of urine specimens.
5. Special Project on Research Excellence: CA-94-31: Principal Investigator: ER Barrack, Ph.D., Co-Investigators: **MP Schoenberg, M.D.** and JM Hakimi, Ph.D. Molecular analysis of androgen receptor structure and function in human prostate cancer.
6. Bladder cancer monitoring program for workers exposed to chlordimeform: Novartis/Allmerica settlement fund. Principal investigator: **M Schoenberg, M.D.**, Co-Investigators: David Sidransky, M.D. and Cheryl Enger, Ph.D., 1998-2002.
7. High throughput genetic analysis of bladder cancer: (NIH) 1p01CA77664-01A1. Co-Investigator: **MP Schoenberg, M.D.**
8. Intravesical Gemcitabine therapy for BCG refractory superficial bladder cancer: A Phase I/II study. Principal investigator: **M Schoenberg, M.D**

9. Carcinoma in Situ in Patients with Bladder Cancer. Photocure. M Droller, M.D., **MP Schoenberg, M.D.** (Begins 9/1/2001)
10. The Effect of Thalomid on COX-2 inhibition and angiogenesis in tumors of patients with invasive bladder cancer. Celgene. **MP Schoenberg, M.D.**
11. Bladder Cancer Microsatellite Analysis of Urinary Sediment. Early Detection Research Network. Grant number U01CA84968. Principal investigator: **MP Schoenberg, M.D.**
12. Microsatellite Analysis of Urinary Sediment in a High Risk Population: Mono and Di-arylamines including dichlorobenzidine, or thotolidine and Ortho-Dianisdine Surveillance Program. Pfizer. (Begins 1/1/06 through 12/31/09) Principal investigator: **MP Schoenberg M.D.**
13. TNG-CL009 A Phase 1 Open Label Exploratory Study of Autologous Neo-Urinary Conduit in Subjects Requiring Incontinent Diversion Following Radical Cystectomy, Principal Investigator: Trinity Bivalacqua, M.D., Co-Investigators: **Mark P. Schoenberg, M.D.** (Began 2010)

X. PUBLICATIONS

1. Schoenberg HW, **Schoenberg MP**, Gregory JG: Anterior bladder tube for continence in neurogenic bladder. *Urology* **5**(6):759-761, 1975.
2. Benz C, **Schoenberg MP**, Choti M, Cadman E: Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. *Journal of Clinical Investigation* **66**(5):1162-5, November, 1980.
3. Guardini MA, **Schoenberg MP**, Naso RA, Martin BA, Gutterman JU, Guevara J: Induction of proteins in human lymphoblastoid cells by recombinant alpha interferon. *Journal of Interferon Research* **4**(1):67-69, 1984.
4. **Schoenberg MP**, Kelly A, Siegel A, Hanno PM, Wein AJ: The Kelly scrotal bridge. *Urology* **31**:521, 1988.
5. Carpiello VL, **Schoenberg MP**, Malloy TR: Long term follow-up of subclinical human papillomavirus infection treated with carbon dioxide laser and intraurethral 5-fluorouracil: treatment protocol. *J Urol* **143**:726-728, April, 1989.
6. **Schoenberg MP** and Pollack HM: The Imaging Corner: Multilocular cystic nephroma. *Contemporary Urology*, November, 1990.
7. **Schoenberg MP**, Van Arsdalen KN, Wein AJ: The management of transitional cell carcinoma in solitary renal units. *J Urol* **146**(3)700-2; discussion 702-3, September, 1991.

8. Carpiello VL and **Schoenberg MP**: Laser treatment of condyloma and other external genital lesions. *Seminars in Urology* **9**(3):175-179, 1991.
9. Shibutani YF, **Schoenberg MP**, Carpiello VL, Malloy TR: Human papillomavirus infection associated with bladder cancer. *Urology* **40**(1):15-17, July, 1992.
10. **Schoenberg MP** and Pollack HM: The Imaging Corner: Congenital mesoblastic nephroma. *Contemporary Urology*, December, 1992.
11. **Schoenberg MP**, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER: Microsatellite mutation (CAG 24-18) in the androgen receptor gene in human prostate cancer. *Biochem. Biophys. Res. Comm.* **198**(1):74-80, 1994.
12. **Schoenberg MP** and Marshall FF: The use of colon segments: orthotopic ileocolic neobladder, *Atlas Urologic Clinics of North America* **3**(2):55-63, 1995.
13. Chang WYH, Cairns P, **Schoenberg MP**, Polascik TJ, Sidransky D: Novel suppressor loci on chromosome 14q in primary bladder cancer. *Cancer Res.* **55**(15):3246-3249, August 1, 1995.
14. **Schoenberg MP**, Cairns P, Brooks JD, Marshall FF, Epstein JI, Isaacs WB, Sidransky D: Frequent loss of chromosomes 8p and 13q in collecting duct carcinoma (CDC) of the kidney. *Genes, Chromosomes & Cancer* **12**:76-80, 1995.
15. Perlman EJ, Brooks J, Gordon AH, Griffin CA, **Schoenberg M**: Embryonal adenoma of the kidney in an adult: case report. *J Urol* **154**:1473-1474, 1995.
16. Rosin MP, Cairns P, Epstein JI, **Schoenberg MP**, Sidransky D: Partial allelotype of carcinoma *in situ* of the human bladder. *Cancer Res.* **55**(22):5213, November, 1995.
17. Polascik TJ, Cairns P, Chang WYH, **Schoenberg MP**, Sidransky D: Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. *Cancer Res.* **55**:5396-5399, November, 1995.
18. Mao L, **Schoenberg MP**, Scicchitano M, Erozan YS, Merlo A, Schwab D and Sidransky D: Molecular detection of primary bladder cancer by microsatellite analysis. *Science* **271**(5249):659-662, February, 1996.
19. **Schoenberg MP**, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB: Local recurrence and survival following nerve sparing radical

cystoprostatectomy for bladder cancer: 10-year followup. *J Urol* **155**:490-494, February, 1996.

20. **Schoenberg M**, Kiemeny L, Walsh PC, Griffin CA, Sidransky D: Germline translocation t (5; 20) (p15; q11) and familial transitional cell carcinoma. *J Urol* **155**:1035-1036, March, 1996.
21. **Schoenberg MP**, Carter HB, Epstein JI: Ureteral frozen-section analysis during cystectomy: a reassessment. *J Urol* **155**:1218-1220, April, 1996.
22. Polascik TJ, Cairns P, Epstein J, Fuzesi L, Sidransky D, **Schoenberg M**: Distal nephron renal tumors: microsatellite allelotype. *Cancer Res.* **56**:1892-1895, 1996.
23. Kiemeny LALM and **Schoenberg M**: Familial transitional cell carcinoma: a review. *J Urol* **156**:867-872, September, 1996.
24. Steiner G, Cairns P, Polascik T, Epstein J, Sidransky D and **Schoenberg M**: High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. *Cancer Res.* **56**:5044-5046, 1996.
25. Hakimi JM, Rondinelli RH, **Schoenberg MP**, Barrack ER: Androgen-receptor gene structure and function in prostate cancer. *World J Urol* **14**:329-337, 1996.
26. Kiemeny LA, Moret NC, Witjes JA, **Schoenberg MP** and Tulinius H: Familial transitional cell carcinoma among the population of Iceland. *J Urol* **157**:1649-1651, May, 1997.
27. Hakimi JM, **Schoenberg MP**, Rondinelli RH, Piantadosi S and Barrack ER: Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. *Clinical Cancer Research* **3**:1-10, 1997.
28. Steiner G, **Schoenberg MP**, Linn JF, Mao L and Sidransky D: Detection of bladder cancer recurrence by microsatellite analysis of urine. *Nature Med* **3**(6):621-624, June, 1997.
29. Linn JF, Lango M, Halachmi S, **Schoenberg MP** and Sidransky D: Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. *Int. J Clin Oncol* **19**; **74**(6):625-9, 1997.
30. Jackman SV, Schulam PG and **Schoenberg MP**: Pseudotumor of the bladder: a late complication of inguinal herniorrhaphy. *Urol* **50**:609-611, 1997.
31. Halachmi S, Enger C, Rosenthal D, Sidransky D and **Schoenberg M**: Molecular diagnosis and staging of bladder cancer. *Molecular Urol* **1**(4):309-314, 1997.

32. Linn JF, Sesterhenn I, Mostofi FK and **Schoenberg M**: The molecular characteristics of bladder cancer in young patients. *J Urol* **159**:1493-1496, May, 1998.
33. Baker LA, Chow N-H, Docimo SG, Gearhart JP, Sidransky D and **Schoenberg M**: Microsatellite deoxyribonucleic acid analysis to detect bladder cancer in bladder exstrophy. *J Urol* **160**:2192-2193, December, 1998.
34. Halachmi S, DeMarzo AM, Linn JF, Epstein JI and **Schoenberg M**: Extensive squamous cell carcinoma in situ of the urinary bladder masking deeply invasive disease. *J Urol* **159**:203, January, 1998.
35. Eisenberger CF, Walsh PC, Eisenberger MA, Partin AW, Mostwin JL, Marshall FF and **Schoenberg M**: Impact of low grade lymphoma on localized prostate cancer management. *Urol* **53**(1):175-9, January, 1999.
36. **Schoenberg M**, Hortopan S, Schlossberg L and Marshall FF: Anatomical anterior exenteration with urethral and vaginal preservation: Illustrated surgical method. *Urol* **161**:569-572, February, 1999.
37. Eisenberger CF, **Schoenberg M**, Fitter D and Marshall FF: Orthotopic ileocolic neobladder reconstruction following radical cystoprostatectomy: history, technique and the results of the Johns Hopkins Experience, 1986-1998. *Urologic Clinics of North America* **26**(1):149-156, February, 1999.
38. Docimo SG, Steiner G, Silver RI, Kinsman S, Sidransky D and **Schoenberg M**: Molecular surveillance for malignancy after augmentation cystoplasty: feasibility and rationale. *Urol* **54**(3):561, September, 1999.
39. Eisenberger CF, **Schoenberg M**, Enger C, Hortopan S, Shah S, Chow N-H, Marshall FF and Sidransky D: Diagnosis of renal cancer by molecular urinalysis. *J Natl Cancer Inst* **91**(23):2028-32, December, 1999.
40. Halachmi S, De Marzo A, Chow NH, Halachmi N, Smith AE, Linn JF, Nativ O, Epstein JI, **Schoenberg MP** and **Sidransky D**: Genetic alterations in urinary bladder carcinosarcoma: evidence of a common clonal origin. *Eur Urol* **37**(3):350-7, March, 2000.
41. Han M and **Schoenberg MP**. : The use of molecular diagnostics in bladder Cancer. *Urol Oncol* **5**:87-92, April, 2000.
42. Han M and **Schoenberg M**: In vitro methods for bladder cancer diagnosis and surveillance. *Urologic Oncology* **5**(3):87-92, Apr-May, 2000
43. Mungan MA, Katja KH, Aben Msc, **Schoenberg MP**, Visser O, Coebergh, J-W, Witjes, JA and Kiemeny, LALM. Gender differences in stage-adjusted bladder cancer survival. *Urology* **55**(6):876-80, June, 2000.

44. Feneley MR and **Schoenberg M**. Bladder sparing strategies for transitional cell carcinoma. *Urology* **56**:549-60, October, 2000.
45. Gonzalgo ML, **Schoenberg MP** and Rodriguez R. Biological pathways to bladder carcinogenesis. *Semin Urol Oncol* **18**:256-63, November, 2000.
46. Chow NH, Cairns P, Eisenberger CF, **Schoenberg MP**, Taylor DC, Epstein JI and Sidransky D: Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. *Int J Cancer* **89**:514-518, November, 2000.
47. Han M, Kronz JD and **Schoenberg MP**. Testicular metastasis of the transitional cell carcinoma of the prostate. *J. Urol.* **164**(6):2026, December, 2000.
48. Laufer M, **Schoenberg MP** and Eisenberger MA. Paclitaxel-induced stomal neuropathy: a unique cause in a patient with ileal conduit. *Urology* **56**(6):1056, December, 2000.
49. Wijkstrom H, Cohen SM, Gardiner RA, Kakizoe T, **Schoenberg M**, Steineck G and Tobisu K: Prevention and treatment of urothelial premalignant and malignant lesions. *Scand J Urol Nephrol Suppl.* (205):116-35, 2000.
50. Han M and **Schoenberg M**: Molecular diagnostics for bladder cancer. *AUA Update Series*, American Urological Association, Inc., Office of Education, Houston, Texas. Lesson 28, Volume XX, 2001.
51. Aben K, Macville M, Smeets D, **Schoenberg M**, Witjes A and Kiemeny LALM: Absence of karyotype abnormalities in patients with familial urothelial cell carcinoma. *Urol.* **57**:266-269, February 2001.
52. Parsons JK and **Schoenberg MP**. Successful conservative management of perforated ileal neobladder. *J. Urol.* **165**:1214-1215, April 2001.
53. **Schoenberg M**. Biomarkers for transitional cell carcinoma (Markers, mom & apple pie). *Urol.* **57**(5):849-851, May, 2001.
54. Parsons JK, **Schoenberg MP** and Carter HB. Incidental Renal Tumors: Casting Doubt on the Efficacy of Early Intervention. *Urol.* **57**(6):1013, June, 2001.
55. Cina SJ, Epstein JI, Endrizzi JM, Harmon WJ, Seay TM and **Schoenberg MP**. Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. *Hum Pathol.* 2001 Jun; **32**(6):630-7.
56. Parsons JK and **Schoenberg MP**. Case Report: Renal artery pseudoaneurysm occurring after partial nephrectomy. *Urol.* **58**(1):105, July, 2001.

57. Levi AW, Potter SR, **Schoenberg MP** and Epstein JI. Clinical significance of denuded urothelium in bladder biopsy. *J. Urol.* **166**:457-460, August 2001.
58. Cairns P, Esteller M, Herman JG, **Schoenberg M**, Jeronimo C, Sanchez-Cespedes M, Chow N-H, Grasso M, Wu L, Westra WB and Sidransky D. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. *Clinical Cancer Research* **7**(9):2727-30, September 2001.
59. Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, Jeronimo C, Jordan RCK, Nicol T, Koch WM, **Schoenberg M**, Mazzarelli P, Fazio VM and Sidransky D: Identification of a mononucleotide repeat as a major target for mitochondrial DNA mutations in human tumors. *Cancer Research* **61**:7015-7019, 2001.
60. **Schoenberg MP**. The William/Buscarini/Stein Article Reviewed. *Onc.* **15**(11):1478.
61. Sachs MD, Rauen KA, Ramamurthy M, Dodson JL, DeMarzo AM, Putzi MJ, **Schoenberg MP** and Rodriguez R. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. *Urology* **60**(3):531-6, September, 2002.
62. Aben KK, Witjes JA, **Schoenberg MP**, Hulsbergen-van de Kaa C, Berbeek AL, Kiemeny LA: Familial aggregation of urothelial cell carcinoma. *Int J Cancer* **98**(2):274-8, March, 2002.
63. Gongalzo ML, Eisenberger CF, Lee SM, Marshall FF, Hortopan S, Sidransky D and **Schoenberg MP**: Prognostic significance of preoperative molecular serum analysis in renal cancer. *Clinical Cancer Research*: 1878-1881 (Vol.8), June 2002.
64. Laufer M, Ramalingam S, **Schoenberg MP**, Haisfield-Wolfe ME, Zuhowski EG, Trueheart IN, Eisenberger M, Nativ O and Egorin MJ. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. *J. Clin. Oncol.* **21**(4):697-703, February, 2003.
65. Tekes A, Kamel IR, Imam K, Chan TY, **Schoenberg MP** and Bluemke DA: MR imaging features of transitional cell carcinoma of the urinary bladder. *AJR Am J Roentgenol.* **180**(3):771-7, March 2003.
66. Tekes A, Kamel IR, Chan TY, **Schoenberg MP** and Bluemke DA. MR imaging features of non-transitional cell carcinoma of the urinary bladder with pathologic correlation. *AJR Am J Roentgenol.* **180**(3):779-84, March 2003.

67. Gonzalgo ML and **Schoenberg MP**: Tailoring surveillance of superficial bladder cancer. *Contemporary Urology* **15**(4):16-39, April, 2003.
68. Hoque MO, Lee C-CR, Cairns P, **Schoenberg M** and Sidransky D: Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. *Cancer Research* **63**(9):2216-2222, May, 2003.
69. Parsons JK, Tufaro A, Chang B and **Schoenberg MP**. Rectus abdominis vaginoplasty after anterior exenteration for urologic malignancy. *Urology* **61**(6):1249-52, June, 2003.
70. Tekes A, Kamel IR, Szarf G, Chan TY, Schoenberg M and Bluemke DA. Carcinosarcoma of the urinary bladder: dynamic contrast-enhanced MR imaging with clinical and pathologic correlation. *AJR Am J Roentgenol.* **181**(1):139-42, July, 2003.
71. Chan D, Ong A and **Schoenberg MP**: Letter to the Editor: Microscopic Hematuria. *N Engl J Med* **349**(13):1292, September, 2003.
72. Hoque MO, Lee J, Betum S, Yamashita K, Engles JM, **Schoenberg M**, Westra WH and Sidransky D: High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. *Cancer Res.* **63**(18):5723-6, September 15, 2003.
73. Hoque MO, Okami K, Steiner G, Engles JM, Osada M, Moon C, Ratovitski E, Trent JM, Meltzer PS, Westra WH, Kiemeny LA, **Schoenberg MP**, Sidransky D and Trink B: CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. *Nature Medicine* **10**(4): 374-81; April, 2004.
74. Sachs MD, Ramamurthy M, Poel H, Wickham TJ, Lamfers M, Gerritsen W, Chowdhury W, Li Y, **Schoenberg MP** and Rodriguez R: Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. *Cancer Gene Therapy* **11**(7):477-86, July, 2004.
75. **Schoenberg M**: Everything old is new again. *J Urol* **172**(3):826, September, 2004.
76. **Schoenberg MP**: What you need to know about bladder cancer. *Bottom Line Health* **18**(9):11, September 2004.
77. Palapattu GS, Bastian PJ, Slavney PR, Haisfield-Wolfe ME, Walker JM, Brintzenhofeszoc K, Trock B, Zabora J and **Schoenberg MP**: Preoperative somatic symptoms are associated with disease progression in patients with

- bladder carcinoma after cystectomy. *Cancer* **101**(10):2209-13, November 15, 2004.
78. Palapattu GS, Haisfield-Wolfe ME, Walker JM, BrintzenhofeSzoc K, Trock B, Zabora J and **Schoenberg M**: Assessment of perioperative psychological distress in patients undergoing radical cystectomy for bladder cancer. *J. Urol.* **172**(5 Pt 1):1814-7, November, 2004.
79. Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, **Schoenberg MP**, Lerner SP and Sagalowsky AI: Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. *J Clin Oncol* **23**(27):6533-9, August 2005.
80. Wang ZG, Durand DB, **Schoenberg M** and Pan YT: Fluorescence guided optical coherence tomography for the diagnosis of early bladder cancer in a rat model. *J Urol* **174**(6):2376-81, December 2005.
81. Tekes A, Kamel I, Imam K, Szarf G, **Schoenberg M**, Nasir K, Thompson R and Bluemke D: Dynamic MRI of bladder cancer: evaluation of staging accuracy. *AJR Am J Roentgenol* **184**(1):121-7, January 2005.
82. Rogers CG, Parwani A, Tekes A, **Schoenberg MP** and Epstein JI: Carcinosarcoma of the prostate with urothelial and squamous components. *J Urol* **173**(2):439-40, February 2005.
83. Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, **Schoenberg MP**, Lerner SP, Sagalowsky AI: Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. Comment in *J. Clin. Oncol.* **23**(27):6450-1, September 2005. Epub August 22, 2005.
84. Wang ZG, Durand DB, **Schoenberg M** and Pan YT: Fluorescence guided optical coherence tomography for the diagnosis of early bladder cancer in a rat model. *J Urol* **174**(6):2376-81, December 2005.
85. Rieder JM, Parsons JK, Gearhart JP and **Schoenberg M**: Primary squamous cell carcinoma in unreconstructed exstrophic bladder. *Urology* **67**(1):199, January 2006.
86. Kiemeny LA, Kuiper RP, Pfundt R, van Reijmersdal S, **Schoenberg MP**, Aben KK, Niermeijer MF, Witjes JA, Schoenmakers EF: No evidence for large-scale germline genomic aberrations in hereditary bladder cancer patients with high-

resolution array-based comparative genomic hybridization. *Cancer Epidemiol Biomarkers Prev* **15**(1): 180-3, January 2006.

87. Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Lotan Y, Vazina A, Gupta A, Sagalowsky AI, Lerner SP and **Schoenberg MP**: Bladder Cancer Reserch Consortium: Cancer specific outcomes in patients with pTO disease following radical cystectomy. *J Urol* **175** (5):1645-9, May 2006.
88. Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, **Schoenberg MP**: Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. *J Urol* **175**(6):2048-53, June 2006.
89. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, **Schoenberg MP**, Lerner SP, Sagalowsky AI, Lotan Y: Discrepancy between clinical and pathologic stage: Impact on prognosis after radical cystectomy. *Eur Urol*, **51**(1):137-49; discussion 149-51, January 2007. Epub June 8, 2006.
90. Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PF, Sagalowsky AI, **Schoenberg M**, Lerner SP: Precystectomy nomogram for prediction of advanced bladder cancer stage. *Eur Urol*, **50**(6):1254-60, December 2006; discussion 1261-2. Epub June 23, 2006.
91. Aben KK, Baglietto L, Baffoe-Bonnie A, Coebergh JW, Bailey-Wilson JE, Trink B, Verbeek AL, **Schoenberg MP**, Alfred Witjes J, Kiemeneij LA. Segregation analysis of urothelial cell carcinoma. *Eur J Cancer* **42**(10):1428-33, July 2006.
92. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, **Schoenberg M**, Zahurak M, Goodman SN, Sidransky D: Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. *J Nat'l Cancer Institute* **98**(14):996-1004, July 19, 2006.
93. Nielsen ME, Schaeffer EM, Veltri RW, **Schoenberg MP**, Getzenberg RH: Urinary markers in the detection of bladder cancer: what's new? *Curr Opin Urol* **16**(5):350-5, September 2006.
94. BHI Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, **Schoenberg MP**, Lerner SP, Sagalowsky AI and Lotan Y: Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology* **68**(3):538-42, September 2006.
95. Karakiwicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, **Schoenberg MP** and Lerner SP: Nomogram for predicting disease recurrence after radical cystectomy for

transitional cell carcinoma of the bladder. *J Urol* **176**(4 Pt 1):1354-61, discussion 1361-2, October 2006.

96. Nielsen ME, Gonzalgo ML, **Schoenberg MP** and Getzenberg RH: Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. *World J Urol* **24**(5):499-508, November 2006.
97. Nielsen ME, Shariat SF, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, **Schoenberg MP** and Palapattu GS for the Bladder Cancer Research Consortium (BCRC): Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. *Eur Urol* **51**(3):699-706; discussion 706-8, March 2007. Epub November 13, 2006.
98. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, **Schoenberg M**, Lerner SP: Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clin Cancer Res* **12**(22):6663-76, November 15, 2006.
99. Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, **Schoenberg M** and Lerner SP: Precystectomy nomogram for prediction of advanced bladder cancer Stage. *Eur Urol* **50**(6):1254-62, December 2006. Epub June 23, 2006.
100. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, **Schoenberg MP** and Lerner SP: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol* **176**(6 Pt 1) 2414-22; discussion 2422, December 2006.
101. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, **Schoenberg MP**, Lerner SP, Sagalowsky AI and Lotan Y: Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined tcc at radical cystectomy. *Eur Urol* **51**(1):152-60, January 2007. Epub September 11, 2006.
102. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, **Schoenberg MP**, Lerner SP, Sagalowsky AI, and Lotan Y: Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol* **51**(1):137-51, January 2007. Epub June 8, 2006.
103. Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, Rodel C, **Schoenberg M**, and Shipley W: Radiotherapy for bladder cancer. *Urology* **69**:80-92, January 2007.

104. Gonzalgo ML, Datar RH, **Schoenberg MP**, and Cote RJ: The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer. *Urologic Oncology* **25**(3):228-35, May-Jun 2007.
105. Tamas EF, Nielsen ME, **Schoenberg MP**, and Epstein JJ: Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. *Mod Pathol* **20**(8):828-34, August 2007, Epub June 1, 2007.
106. Semins MJ and **Schoenberg MP**: A case of florid cystitis glandularis. *Nat Clin Pract Urol* **4**(6):341-5, June 2007.
107. Bivalacqua TJ, Alphs H, Aksentijevich I, Schaeffer EM and **Schoenberg MP**: Paraneoplastic polyarthritis from non-small-cell lung cancer metastatic to the bladder. *J Clin Oncol* **25**(18):2621-3, June 2007.
108. Berndt SI, Carter HB, **Schoenberg MP** and Newschaffer CJ: Disparities in treatment and outcome for renal cell cancer among black and white patients. *J Clin Oncol* **25**(24):3589-95, August 2007.
109. Nielsen ME, Palapattu GS, Karakiewicz PI, Lotan Y, Bastian PJ, Lerner SP, Sagalowsky AI, **Schoenberg MP** and Shariat SF: A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. *BJU Int* **100**(5):1015-20, November 2007, Epub September 3, 2007.
110. Bastian PJ, Hutterer GC, Shariat SF, Rogers CG, Palapattu GS, Lotan Y, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, **Schoenberg MP** and Karakiewicz PI – From the Bladder Cancer Research Consortium: Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. *BJU Int.* **101**(4):450-4, February 2008, Epub September 10, 2007.
111. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenous C, Nseyo U, Droller MK, Albala D, Babayan R, Bihle W, Cookson M, Fuchs G, Lerner S, Malkowicz B, Pruthi R, **Schoenberg M**, Zippe C, Lange N and Bostwick DG: A phase III, multicenter comparison of hexaminolevulinate (HAL) fluorescence cystoscopy and white light cystoscopy for the detection of superficial and papillary lesions in patient with bladder cancer. *J Urol* **178**(1):62-7, July 2007.
112. Nielsen ME, Bastian PJ, Palapattu GS, Trock BJ, **Schoenberg MP**, Chan T and Rogers CG: Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection. *Urology* **70**(6):1091-5, December 2007.
113. Gupta A, Lotan Y, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, **Schoenberg MP**, Lerner SP, Sagalowsky AI, Shariat SF; Bladder Research Consortium: Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. *Urology* **71**(2):302-7, February 2008.

114. Wagner KR, **Schoenberg MP**, Bianco FJ Jr, Jarrett TW: Prospective Intermediate follow-up of carcinoma in situ involving the distal ureter at cystectomy: is there a role for ureteroscopy? *J Endourol* **22**(6):1241-6, June 2008.
115. Walz J, Shariat SF, Suardi N, Perrotte P, Lotan Y, Palapattu GS, Gupta A, Bastian PJ, Rogers CGT, Vazina A, Amiel GE, Sagalowsky AI, **Schoenberg M**, Lerner SP, Karakiewicz PI. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. *SJU Int* **101**(11):1356-61, June 2008.
116. Guzzo TJ, Bivalacqua TJ, **Schoenberg MP**: Bladder cancer and the aluminum industry: a review. *BJU Int.* **102**(9):1058-60, November 2008.
117. Alphas HH, Miles-Thomas J, Attenello F, Taube JM, Fonseca G, Guzzo TJ, **Schoenberg MP**, Bivalacqua TJ: Presentation and management of a patient with subcutaneous metastatic transitional cell carcinoma of the bladder. *Nat Clin Pract Urol* **5**(12):691-4, December 2008.
118. Guzzo TJ, Rogers CG, Deng CY, Bivalacqua TJ, Palapattu GS, Bastian PJ, Eisenberger MA, **Schoenberg MP**, Gonzalgo ML: Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease. *BJU Int.* **102**(11):1539-43, December 2008.
119. Loeb S, Lotan TL, Thornton K, Gearhart SL, **Schoenberg MP**: A case of gastrointestinal stromal tumor diagnosed on prostate biopsy. *Nat Clin Pract Urol* **6**(1):54-7, January 2009.
120. Capitanio U, Suardi N, Shariat SF, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, **Schoenberg M**, Lerner SP, Sagalowsky AI, Karakiewicz PI: Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. *BJU Int* **103**(10):1359-62, May 2009.
121. Isbarn H, Karakiewicz PI, Shariat SF, Capitanio U, Palapattu GS, Sagalowsky AI, Lotan Y, **Schoenberg MP**, Amiel GE, Lerner SP, Sonpavde G: Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. *J. Urol.* **182**(2):459-65; discussion 465, August 2009, Epub June 13, 2009.
122. Guzzo TJ, Magheli A, Bivalacqua TJ, Nielsen ME, Attenello FJ, **Schoenberg MP**, and Gonzalgo ML. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette Guerin-refractory bladder cancer. *Urology* **74**(8):1276-80, December 2009.

123. Vickers AJ, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH; **International Bladder Cancer Consortium**. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. *Cancer*. 2009 Dec 1;115(23):5460-9. doi: 10.1002/cncr.24615. Erratum in: *Cancer*. 2011 Aug 15;117(16):3867.
124. Bivalacqua TJ, Loeb S, Pierorazio PM, **Schoenberg MP**, Partin AW, Guzzo TJ. Is prostate-specific antigen surveillance necessary in men with benign prostate pathology following radical cystoprostatectomy for bladder cancer? *Urol Int*. 2010;85(4):466-9. doi: 10.1159/000321693. Epub 2010 Nov 13. PMID: 21071926 [PubMed - indexed for MEDLINE]
125. Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, **Schoenberg M**, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. *J Urol* **183**(1):87-93, January 2010.
126. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, **Schoenberg M**, Kamat A, Dinney CP, Lotan Y, Shariat SF. Characteristics and outcomes of patients with clinical T1 Grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol*. 2010 Feb;57(2):300-9. doi: 0.1016/j.eururo.2009.09.024. Epub 2009 Sep 12. PMID: 19766384 [PubMed - indexed for MEDLINE]
127. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, **Schoenberg MP**, Witjes JA, Kiemeny LA. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. *J Urol*. **183**(3):915-20 2010, March 2010, Epub Jan 18, 2010.
128. **Schoenberg MP**. Introduction to the BCAN seminar section. *Urol Oncol*. 2010 May-Jun;28(3):328. doi: 10.1016/j.urolonc.2010.03.020. No abstract available. PMID: 20439031 [PubMed - indexed for MEDLINE]
129. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JI, Lerner SP, **Schoenberg MP**, Stief CG, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. *J Urol*. 2010

May;183(5):1757-63. doi: 10.1016/j.juro.2010.01.025. Epub 2010 Mar 17.
PMID: 20299059 [PubMed - indexed for MEDLINE]

130. Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, **Schoenberg MP**, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y., International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU Int.* **105**(10):1402-12, May 2010, Epub Feb 2, 2010.
131. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, Lerner SP, **Schoenberg MP**, Volkmer BG, Sagalowsky AI, Shariat SF: Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. *J Urol.* **183**(6):2165-70, June 2010.
132. Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, Schaeffer EM, **Schoenberg MP**, Walsh PC, Partin AW. Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. *Urology* **76**(3):715-21, September 2010, Epub Mar 29, 2010.
133. Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, **Schoenberg MP**, Stief CG, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Reich O, Shariat SF: Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. *J Urol.* **184**(3):888-94, September 2010.
134. Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, **Schoenberg MP**, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. *Clin Cancer Res.* **16**(17):4461-7, September 2010, Epub Jul 22, 2010.
135. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Neilsen ME, Gonzalgo ML, Sidransky D, **Schoenberg M**, Netto GJ., Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. *Cancer.* **116**(23):5517-26, December 2010, doi: 10.1002/cncr.25502. Epub October 11, 2010.
136. Bivalacqua TJ, Loeb S, Pierorazio PM, **Schoenberg MP**, Partin AW, Guzzo TJ.: Is prostate-specific antigen surveillance necessary in men with benign prostate pathology following radical cystoprostatectomy for bladder cancer? *Urol Int.* **85**(4):466-9, 2010. Epub November 13, 2010.

137. Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, **Schoenberg M**, Sagalowsky AI, Lotan Y, Shariat SF: Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. *J Urol*. **185**(2):456-61, February 2011. Epub December 17, 2010.
138. Brown SC, Alberts R, **Schoenberg M.**, Cancer incidence and mortality among workers exposed to benzidine. *Am J Ind Med*. February 15, 2011. Doi: 10.1002/ajim.20936. [Epub ahead of print]
139. Guzzo TJ, Hockenberry MS, Mucksavage P, Bivalacqua TJ, **Schoenberg MP.** Smoking Knowledge Assessment and Cessation Trends in Patients With Bladder Cancer Presenting to a Tertiary Referral Center. *Urology*. 2012 Jan; 79(1):166-71. Epub 2011 Oct 26.
140. Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ and **Schoenberg MP.** The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. *Urol Oncol*. 2012 Jan-Feb;30(1):44-8. doi: 10.1016/j.urolonc.2009.10.008. Epub 2009 Dec 16. PMID: 20005748 [PubMed - indexed for MEDLINE]
141. Mullins JK, Guzzo TJ, Ball MW, Pierorazio PM, Eifler J, Jarrett TW, **Schoenberg MP**, Bivalacqua TJ. Ureteral Stents Placed at the Time of Urinary Diversion Decreases Postoperative Morbidity. *Urol Int*. 2012 Jan 4. [Epub ahead of print]
142. Hyndman ME, Kaye D, Field NC, Lawson KA, Smith ND, Steinberg GD, **Schoenberg MP**, Bivalacqua TJ. The use of regenerative medicine in the management of invasive bladder cancer. *Adv Urol*. 2012; 2012:653652. Epub 2012 Aug 27.
143. Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, **Schoenberg MP**, Netto GJ, Gonzalgo ML. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. *Urol Oncol*. 2011 Mar 9. [Epub ahead of print]
144. Gupta AD, Streiff M, Resar J, **Schoenberg M.** Coronary stent management in elective genitourinary surgery. *BJU Int*. 2011 Dec 22. doi: 10.1111/j.1464-410X.2011.10821.x. [Epub ahead of print]
145. Droller MJ; ad hoc Committee on Plagiarism, Bahnson RR, Lerner SP, **Schoenberg M**, Thalmann GA. Plagiarism. *Urol Oncol*. 2012 Sep; 30(5):547-8. doi: 10.1016/j.urolonc.2012.06.004. No abstract available.

146. Chaux A, Cohen JS, Schultz L, Albadine R, Jadallah S, Murphy KM, Sharma R, **Schoenberg MP**, Netto GJ. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. *Hum Pathol.* 2012 Oct;43(10):1590-5. doi: 10.1016/j.humpath.2011.11.016. Epub 2012 Mar 9. PMID: 22406363 [PubMed - indexed for MEDLINE]
147. Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; **Bladder Cancer Research Consortium (BCRC)**; Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *Eur Urol.* 2012 Oct;62(4):677-84. Epub 2012 Feb 15. PMID: 22349570 [PubMed - indexed for MEDLINE]
148. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, **Schoenberg MP**, Sagalowsky AI, Soloway MS, Stenzl A. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. *Eur Urol.* 2013 Jan; 63(1):45-57. doi: 10.1016/j.eururo.2012.08.009. Epub 2012 Aug 14. PMID: 22917985[PubMed - in process]
149. Segal RL, Readal N, Pieororazio PM, Kutlu O, **Schoenberg M**, Bivalacqua TJ. Radical Cystectomy in Patients with Preexisting Three-Piece Inflatable Penile Prosthesis. *J Sex Med.* 2013 Feb; 10(2):595-8. doi: 10.1111/j.1743-6109.2012.02980.x. Epub 2012 Oct 22. PMID: 23088759 [PubMed - in process]
150. Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; **Bladder Cancer Research Consortium**. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int.* 2013 Mar; 111(3 Pt B):E30-6. doi: 10.1111/j.1464-410X.2012.11433.x. Epub 2012 Sep 3. PMID: 22938654 [PubMed - indexed for MEDLINE]
151. Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, **Schoenberg MP**, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in

urothelial carcinoma of bladder. *Urol Oncol*. 2013 May; 31(4):480-6. doi: 10.1016/j.urolonc.2011.02.011. Epub 2011 Apr 8. PMID: 21478035 [PubMed - in process]

152. Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, **Schoenberg MP**, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. *BJU Int*. 2013 Jun;111(8):1215-21. doi: 10.1111/j.1464-410X.2012.11455.x. Epub 2012 Nov 26.
153. Kinde I, Munari E, Faraj SF, Hruban RH, **Schoenberg M**, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ. TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. *Cancer Res*. 2013 Dec 15; 73(24):7162-7. doi: 10.1158/0008-5472.CAN-13-2498. Epub 2013 Oct 11.
154. Kates M, Gorin MA, Deibert CM, Pierorazio PM, **Schoenberg MP**, McKiernan JM, Bivalacqua TJ. In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States. *Urol Oncol*. 2014 Jan; 32(1):53.e9-53.e14. doi: 10.1016/j.urolonc.2013.08.024. Epub 2013 Nov 13.
155. Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, **Schoenberg M**, Seigne J, Vikram B. Clinical Trial Design for the Development of New Therapies for Non-Muscle-Invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop. *Urology*. 2013 Dec 11. pii: S0090-4295(13)01375-7. doi: 10.1016/j.urology.2013.10.030. [Epub ahead of print]
156. Gorin MA, Kates M, Mullins JK, Pierorazio PM, Matlaga BR, **Schoenberg MP**, Bivalacqua TJ. Impact of hospital volume on perioperative outcomes and costs of radical cystectomy: analysis of the Maryland Health Services Cost Review Commission database. *Can J Urol*. 2014 Feb; 21(1):7102-7. PMID: 24529009 [PubMed - in process]
157. Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, **Schoenberg MP**, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: Review of the clinical evidence and consensus statement on appropriate use in the

- USA. *Nat Rev Urol*. 2014 Oct; 11 (10): 589-96.doi: 10.1038/nrurol. 2014.245. Epub 2014 Sep 23.
158. Faraj SR, Chaux A, Gonzalez-Roibon N, Munari E, Ellis C, Driscoll T, **Schoenberg MP**, Bivalacqua TJ, Shih IM, Netto GJ. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. *Hum Pathol*. 2014 Jul 23. pii: S0046-8177 (14) 00285-8.doi: 10.1016/J.Humpath.2014.07.003. [Epub ahead of print]
159. Jarrow J, Kluetz PG, Lerner SP, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, **Schoenberg MP**. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. *Urology*. 2014 Aug; 84(2):495-6.
160. Reese AC, Ball MW, Gandhi N, Gorin MA, Netto GJ, Bivalacqua TJ, **Schoenberg MP**. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer. *Urology*. 2014 Aug; **84**(2): 358-63.
161. Bezerra SM, Lotan TL, Faraj SF, Karam S, Sharma R, **Schoenberg MP**. GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. *Hum Pathol*. 2014 Aug; **45**(8): 1682-7.
162. Hayashi M, Bernert H, Kagohara LT, Maldonado L, Brait M, **Schoenberg MP**. Bivalacqua T, Netto GJ, Koch W, Sidransky D, Hoque MO. Epigenetic inactivation of VGF associated with urothelial cell carcinoma and its potential as a non-invasive biomarker using urine. *Oncotarget*. 2014 May 30; **5**(10):3350-61
163. Gonzalez-Roibon N, Kim JJ, Faraj SF, Chaux A, Bezerra SM, Munari E, Ellis C, Sharma R, Keizman D, Bivalacqua TJ, **Schoenberg MP**. Eisenberger M, Carducci M, Netto GJ. Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: A retrospective study of patients treated using radical cystectomy. *Urology*. 2014 Jun; **83**(6):1444.e1-6.doi:10.1016/ J. Urology.2014.01.028 [Epub 2014 Apr 6]

XI. BOOK CHAPTERS AND BOOKS

1. Hakimi JM, Rondinelli RH, **Schoenberg MP**, Barrack ER: Androgen receptors in human prostate cancer: heterogeneous expression, gene mutations and polymorphic variants. *Hormones and Cancer* **16**:449-496, Birkhäuser Boston, January, 1996.
2. **Schoenberg M**: Molecular diagnostics and bladder cancer. *Das oberflächliche Harnblasen-karzinom - eine lebenslange panurotheliale Erkrankung?* Logos Verlag Berlin 45-51, 1996.
3. The Guide to Living with Bladder Cancer. **Mark P. Schoenberg, M.D.** The Johns Hopkins University Press, Baltimore, MD, 2000.
4. **Schoenberg M**: Chapter 78: Management of Invasive and Metastatic Bladder Cancer. *Campbells Urology*, Eighth Edition. W.B. Saunders, 2002.
5. Linn JF, Halachmi S and **Schoenberg MP**: Chapter 4: Bladder and other urothelial malignancies. *Atlas of Genitourinary Oncology*, W.B. Saunders Company, 2002.
6. Urothelial Tumors. Chapter 6. Editor: Droller M. BC Decker Inc; 2004.
7. Gonzalgo ML and **Schoenberg MP**: Chapter: DNA Methylation in Development of Bladder Cancer. *Bladder Cancer: From the Laboratory to Clinical Practice*, Editor: Droller, M. In press.
8. Textbook of Bladder Cancer. Editors: Lerner SP, **Schoenberg MP**, and Sternberg CN. Taylor & Francis, 2006.
9. Schaeffer EM, Nielson ME, Gonzalgo, ML and **Schoenberg MP**: Chapter: Nerve Sparing Radical Cystectomy. *Bladder Cancer: Diagnosis, Therapeutics, and Management*, Editors: Cheryl T. Lee and David P. Wood. In press.
10. **Schoenberg, MP**: ICUD Guidelines on Bladder Cancer. Chapter 6: 6.1, 2011.

XII. PRESENTATIONS TO LEARNED SOCIETIES

1. **Schoenberg MP**, Goldstein L, Watson L and Thompson JC: Separation of cholecystokinin from gastrin by analytical isoelectric focusing. *Gastroenterology American Gastroenterological Association Program*, New York, NY, May, 1981.
2. Carpinello VL, **Schoenberg MP**, Zderic S and Malloy TR. CO₂ Laser and 5-fluorouracil treatment of subclinical condylomatous disease: long-term follow-up. Presented at the Annual American Urological Association Meeting, Dallas, TX, May 7-11, 1989. *J Urol* **141**:251A (Abstract #328), 1989.
3. Shibusani YF, **Schoenberg MP**, Carpinello VL and Malloy TR. Human papillomavirus infection associated with bladder cancer. Presented at the Mid-

- Atlantic Section Meeting, American Urological Association, Richmond, VA, 1990.
4. **Schoenberg MP**, Van Arsdalen KN and Wein AJ. Management of transitional cell carcinoma in solitary renal units. Presented at the Mid-Atlantic Section Meeting, American Urological Association, Richmond, VA, October, 1990.
 5. **Schoenberg MP**, Tonb DC, Brown TR and Barrack ER. Functional analysis of an androgen receptor (AR) gene mutation in localized human prostate cancer. Presented at the 7th Annual Meeting, Society for Basic Urologic Research, San Antonio, TX, May 14-15, 1993.
 6. Bussemakers MJG, Bova GS, **Schoenberg MP**, Hakimi JM, Barrack ER and Isaacs WB. Microsatellite instability in human prostate cancer. Presented at the American Urological Association Annual Meeting, San Francisco, CA, May 14-19, 1994. *J Urol* **151**:469A (Abstract #967), 1994.
 7. **Schoenberg MP**, Hakimi, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC and Barrack ER. Microsatellite mutation (24-18) in the androgen receptor gene in human prostate cancer. American Association of Cancer Research National Meeting in San Francisco, CA, April 12, 1994 and American Urological Association Annual Meeting, San Francisco, CA, May 14-19, 1994. *J Urol* **151**:458A (Abstract #923), 1994.
 8. **Schoenberg MP**, Hakimi JM and Barrack ER. Allele size distribution of the androgen receptor (AR) CAG microsatellite in human prostate cancer. Presented at the 8th Annual Meeting of the Society for Basic Urologic Research, May 13-14, 1994, San Francisco, CA.
 9. **Schoenberg MP**, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL and Brendler CB. Local recurrence and survival following nerve sparing radical cystoprostatectomy: 10-year followup. Presented at the American Urological Association Annual Meeting in Las Vegas, NV, April 23-28, 1995. *J Urol* **155**:490-494. (Abstract #657), 1995.
 10. Polascik TJ, Brooks JD, Marshall FF, Epstein JI, Isaacs W, Fuzesi L, Ro J, Sidransky D and **Schoenberg MP**. Frequent loss of heterozygosity on chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Presented at the American Urological Association Annual Meeting, April 23-28, 1995, Las Vegas, NV. (Abstract #1068) 1995.
 11. Hakimi JM, **Schoenberg MP** and Barrack ER. Androgen receptor variants as a potential risk factor for aggressive prostate cancer. Presented at the American

Urological Association Annual Meeting, April 23-28, 1995, Las Vegas, NV. (Abstract # 216), 1995.

12. **Schoenberg MP**, Polascik TJ, Chang WYH, Cairns P and Sidransky D. Microsatellite allelotype of chromosome 4 in human invasive bladder carcinoma. Presented at the American Urological Association Annual Meeting, April 23-28, 1995, Las Vegas, NV. (Abstract #542), 1995.
13. Mao L, **Schoenberg MP**, Scicchitano M, Erozan YS, Merlo A, Schwab D and Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Presented at the American Urological Association Annual Meeting in Orlando, FL, May 4-9, 1996. Abstract #1221). 1996.
14. Polascik, Cairns P, Epstein JI, Fuzesi L, Ro JY, Marshall FF, Sidranski D and **Schoenberg M**. Distal nephron renal tumors: microsatellite allelotype. Presented at the American Urological Association Annual Meeting in Orlando, FL, May 4-9, 1996. (Abstract #417), 1996.
15. Kiemeney LA, Moret NC, Witjes JF, **Schoenberg MP** and Tulinius H. Familial aggregation of transitional cell carcinoma of the urinary tract. Presented at the American Urological Association Annual Meeting in Orlando, FL, May 4-9, 1996. (Abstract #1520). 1996.
16. Steiner G, Cairns P, Polascik TJ, Sidransky D and **Schoenberg M**. Chromosomal arm 1q loss in collecting duct carcinoma: region of minimal deletion at 1q31-32.3. Presented at the American Urological Association Annual Meeting in Orlando, FL, May 4-9, 1996. (Abstract #414), 1996.
17. **Schoenberg M**, Carter HB, Mostwin JL, Burnett AL, and Marshall FF. Male orthotopic ileocolic neobladder post cystectomy: long term follow-up. Presented at the American Urological Association Annual Meeting in Orlando, FL, May 4-9, 1996. (Abstract #828), 1996.
18. Steiner G, **Schoenberg M**, Cairns P and Sidransky D. High density mapping of chromosomal arm 20q in bladder carcinoma: definition of a breakpoint at 20q11:23. Presented at the American Urological Association Annual Meeting in New Orleans, LA, April 12-17, 1997. (Abstract #104), 1997.
19. Linn JF, Sesterhenn I, Mostofi F and **Schoenberg MP**. Molecular characteristics of transitional cell carcinoma in childhood. Presented at the American Urological Association Annual Meeting in New Orleans, LA, April 12-17, 1997. (Abstract #587), 1997.
20. Mosher TJ, Bluemke DA, Fishman EK, **Schoenberg MP**, Eisenberger M and DeWeese TL. Multimodality treatment planning for bladder cancer: MR and CT

evaluation. Presented at the American Roentgen Ray Society in Boston, MA, May 4-9, 1997.

21. Chow N-H, Trink B, Eisenberger C, **Schoenberg M** and Sidransky: Tyrosine kinase profile of bladder cancer. Presented at the American Urological Association Annual Meeting in San Diego, CA, May 30-June 4, 1998, (Abstract #1096), 1998.
22. Cairns P, Grasso M, Chow N-H, **Schoenberg M**, Sidransky D: Molecular detection of genetic alterations in urine and serum from prostate cancer patients. Presented at the American Urological Association Annual Meeting, San Diego, CA, May 30-June 4, 1998, (Abstract #272), 1998.
23. Eisenberger CF, **Schoenberg M**, Enger C, Hortopan S, Shah S, Chow N-H, Marshall FF and Sidransky D: Diagnosis of renal cancer by molecular analysis. Presented at the American Urological Association Annual Meeting, Dallas, TX, May 1-6, 1999.
24. Chow N-H, Cairns P, Eisenberger CF, **Schoenberg M**, Taylor DC, Epstein JI and Sidransky D: Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Presented at the American Urological Association Annual Meeting, Dallas, TX, May 1-6, 1999.
25. **Schoenberg M**, Peralta C, Kiemeny LALM and Fleisher L. A contemporary analysis of superficial bladder cancer monitoring - the Johns Hopkins Experience (1977 - 1997). Presented at the American Urological Association Annual Meeting, Atlanta, Georgia, May 1, 2000.
26. Levi AW, Potter SR, **Schoenberg MP** and Epstein JI. Denuded urothelium in bladder biopsies. Presented at the American Urological Association Annual Meeting, Atlanta, Georgia, May 1, 2000.
27. Endrizzi J, Cina S, Harmon W, Seay T, **Schoenberg M** and Epstein J. Correlation of cystoscopic impression and histologic diagnosis of biopsy specimens of the bladder. Presented at the American Urological Association Annual Meeting, Atlanta, Georgia, May 1, 2000.
28. Mungan NA, Aben KKH, **Schoenberg MP**, Visser O, Coebergh J-W, Witjes JA and Kiemeny LALM. Gender differences in stage-adjusted bladder cancer survival. Presented at the American Urological Association Annual Meeting, Atlanta, Georgia, May 1, 2000.
29. Bishoff JT, Harmon WJ, **Schoenberg MP** and Kavoussi LR. Laparoscopic partial nephrectomy for T1 renal cell carcinoma. Presented at the American Urological Association Annual Meeting, Atlanta, Georgia, May 1, 2000.

30. Lee CR, **Schoenberg M**, Westra WH, Hudson MA, Lerner SP, Messing EM and Sidransky D. A prospective, randomized, multi-institutional trial for the molecular detection and monitoring of urinary bladder cancer patients.
31. Ramamurthy M, Dodson J, DeMarzo A, **Schoenberg M** and Rodriguez R. Evaluation of the susceptibility of clinical superficial bladder cancers to adenoviral gene therapy: an analysis of Coxsackie adenovirus receptor expression. Presented at the 92nd Annual Meeting of the American Association for Cancer Research, New Orleans, LA, March, 2001.
32. Gonzalgo ML, Eisenberger CF, Hortopan S, Sidransky D, **Schoenberg MP** and Marshall FF. Prognostic Significance of Preoperative Molecular Urinalysis in Renal Cancer. Presented at the Annual AUA Meeting, Anaheim, CA, June, 2001.
33. Sachs MD, Ramamurthy M, Dodson J, Van der Poel, H, Demarzo A, Rauen K, **Schoenberg MP** and Rodriguez R. Susceptibility of clinical bladder cancer to adenoviral gene therapy. Presented at the Annual AUA Meeting, Orlando, Florida, 2002.
34. Kiemeny LA, Aben K, Verbeek A, Witjes A, Baffoe-Bonnie A and **Schoenberg MP**. Familial aggregation of urothelial cell carcinoma. Presented at the 94th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, 2003.
35. Hoque MO, Lee J, Begum S, Yamashita K, **Schoenberg MP**, Westra WM and Sidransky D. Presented at the 94th Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, 2003.
36. Ellison L and **Schoenberg MP**. Is patient survival an appropriate measure of the utility of radical cystectomy in octogenarians? Presented at the Annual AUA Meeting, Chicago, IL, 2003.
37. Halachmi S, Cohen M, Shargal R, Cohen N, Israel H and **Schoenberg MP**. Completely automated microcapillary microsatellite analysis for bladder cancer detection. Presented at the Annual AUA Meeting, Chicago, IL, 2003.
38. Kimeny LA, Aben K, Verbeek A, Witjes A, Baffoe-Bonnie A and **Schoenberg MP**. Familial Aggregation of urothelial cell carcinoma. Presented at the Annual AACR Meeting, Toronto, Ontario, Canada, 2003.
39. Hogue MO, Lee J, Begum S, Yamashita K, **Schoenberg MP**, Westra WM and Sidransky D. Highthroughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Presented at the Annual AACR Meeting, Toronto, Ontario, Canada, 2003.

40. Marshall FF and **Schoenberg MP**: Cystectomy and the management of muscle invasive bladder cancer. Presented at the American Urological Association Annual Meeting in Chicago, IL, April, 2003.
41. **Schoenberg MP**: *In Vitro* Diagnosis of Bladder Cancer: At Last, a Multi-Center, NCI-funded Trial. Presented at The Maryland Urological Association Meeting, Johns Hopkins Medical Institutions, Baltimore, Maryland, November 22, 2003.
42. Haisfield-Wolfe ME, **Schoenberg M**, Welch J and Huang Y: Improving the quality of continence for bladder cancer patients' recovery after a cystectomy with neobladder reconstruction (Poster). Presented at the Oncology Nursing Society Convention, Anaheim, CA, April 29, 2004.
43. Grossman HB, Gomella LG, Fradet Y, Presti JC, Ritenour CWM, Lerner SP, Cookson M, Nseyo UO, Bihrl R, Fuchs GJ, **Schoenberg MP** and Droller MJ: The use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage Ta/T1 urothelial cancer in the urinary bladder. Presented at the Annual American Urological Association Meeting in San Francisco, CA, May, 2004.
44. Welch J, **Schoenberg M**, Haisfield-Wolfe ME and Huang BS: Improving Continence after a Cystectomy with Neobladder Reconstruction. Presented at the American Physical Therapy Association Meeting, 2004.
45. Karakiewicz PI, Shariat SF, Perrotte P, Palapattu GS, Rogers CG, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, **Schoenberg MP** and Lerner SP: A prognostic tool to identify patients at high risk of relapse at 2, 5 and 8 years after cystectomy for transitional cell carcinoma (tcc) of the urinary bladder: nomogram development and internal validation. Presented at the Annual American Urological Association Meeting in San Antonio, TX, May, 2005.
46. Rogers CG, Palapattu GS, Bastian PJ, Gonzalgo ML and **Schoenberg MP**: Outcomes of patients with aborted cystectomy for intraoperative findings of metastatic disease. Presented at the Annual American Urological Association Meeting in San Antonio, TX, May, 2005.
47. Palapattu GS, Karakiewicz PI, Bastian PJ, Rogers CG, Shariat SF, Lotan Y, Gupta A, Vazina A, Amiel GE, Perrotte P, Sagalowsky AI, Lerner SP and **Schoenberg MP**: Are patients who are pT0 following radical cystectomy cured of bladder cancer? Results from the Bladder Cancer Research Consortium (BCRC). Presented at the Annual American Urological Association Meeting in San Antonio, TX, May, 2005.

48. Rogers CG, Palapattu GS, Karakiewicz PI, Bastian PJ, Shariat SF, Lotan Y, Gupta A, Vazina A, Amiel GE, Perrotte P, Sagalowsky A, Lerner SP and **Schoenberg MP**: Bladder cancer-specific survival following radical cystectomy for primary non-transitional cell carcinoma (non-tcc) of the bladder: results from the Bladder Cancer Research Consortium (BCRC). Presented at the Annual American Urological Association Meeting in San Antonio, TX, May, 2005.
49. Amiel GE, Shariat SF, Shen S, Palapattu GS, Lotan Y, Karakiewicz PI, Vazina A, Rogers CG, Bastian PJ, Nielsen ME, Gupta A, **Schoenberg MP**, Sagalowsky AI, Lerner SP: Evidence based gender related outcomes after radical cystectomy. Presented at the Annual American Urology Association Meeting in Atlanta, Georgia, May, 2006.
50. Nielsen ME, Shariat SF, Karakiewicz PI, Amiel GE, Rogers CG, Lotan Y, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, **Schoenberg MP**, Palapattu GS: Delay in radical cystectomy over 12 weeks is not associated with adverse outcome: Results from the Bladder Cancer Research Consortium. Presented at the Annual American Urology Association Meeting in Atlanta, Georgia, May, 2006.
51. Briganti A, Chun K-H F, Shariat SF, Lotan Y, Palapattu GS, Rogers CG, Bastian PJ, Gilad A, Gupta A, Vazina A, Sagalowsky AI, Lerner SP, **Schoenberg MP**, Karakiewicz PI: Internal validation of a competing-risks survival nomogram for patients treated with cystectomy for bladder cancer. Presented at the Annual American Urology Association Meeting in Atlanta, Georgia, May, 2006.
52. Shariat SF, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Bastian PJ, Vazina A, Gupta A, **Schoenberg MP**, Lerner SP, Sagalowsky AI, Lotan Y: Impact of concomitant carcinoma in situ on clinical outcomes after radical cystectomy. Presented at the Annual American Urology Association Meeting in Atlanta, Georgia, May, 2006.
53. Bastian PJ, Shariat SF, Rogers CG, Amiel GE, Karakiewicz PI, Lotan Y, Gupta A, Vazina A, Sagalowsky AI, Lerner SP, **Schoenberg MP**, Palapattu GS: Prognostic significance of deep muscular invasion and intravesical extension in pathological staging of bladder cancer after radical cystectomy. Presented at the Annual American Urology Association Meeting in Atlanta, Georgia, May, 2006.
54. Chun K-H F, Briganti A, Shariat SF, Palapattu GS, Lotan Y, Rogers CG, Bastian PJ, Amiel GE, Gupta A, Vazina A, Nielsen M, Sagalowsky AI, Lerner SP, **Schoenberg MP**, Karakiewicz PI: Competing risks nomogram predicting the probability of bladder cancer recurrence after cystectomy can reliably distinguish between those destined to recur and those who may die of other causes before recurrence. Presented at the Annual American Urology Association Meeting in Atlanta, Georgia, May, 2006.

55. Gupta A, Shariat SF, Nielson M, Bastian PJ, Palapattu GS, Rogers CG, Vazina A, Karakiewicz PI, **Schoenberg MP**, Lerner SP, Sagalowsky AI, Lotan Y: Outcomes of patients with T1 grade 3 bladder urothelial cell bladder carcinoma treated with radical cystectomy. Presented at the Annual American Urology Association Meeting in Anaheim, California, May, 2007.
56. Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, **Schoenberg MP**, Walsh PC, Partin AW. Long-term survival after radical prostatectomy for men with high pathologic gleason sum. Presented at the Annual American Urology Association Meeting in Chicago, IL, April, 2009.
57. Svatek RS, Shariat SF, Kassouf W, Novara G, Fradet Y, Bastian PJ, Karakiewicz PI, Fritsche H-M, Muller SC, Izawa JI, Dinney CP, Stief CG, Ficarra V, Kamat A, Isbarn H, Lerner SP, Sagalowsky AI, **Schoenberg MP**, Lotan Y, Skinner E. Prognostic value of lymph node density in a multicenter international cohort of patients with node positive urothelial carcinoma of the bladder. Presented at the Annual American Urology Association Meeting in Chicago, IL, April, 2009.
58. Novara G, Svatek RS, Karakiewicz, PI, Skinner E, Fradet Y, Lotan Y, Capitanio U, Bastian PJ, Montorsi F, Kassouf W, Fritsche H-M, Muller SC, Izawa JI, Isbarn H, Stief CG, Vacarra V, Dinney CP, Lerner SP, **Schoenberg MP**, Sagalowsky AI, Kamat A, Volkmer BG, Shariat SF. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of over 4800 patients. Presented at the Annual American Urology Association Meeting in Chicago, IL, April, 2009.
59. Svatek RS, Shariat SF, Dinney CP, Novara G, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche H-M, Muller SC, Izawa JI, Skinner E, Stief CG, Ficarra V, Volkmer BG, Montorsi F, Isbarn H, Lerner SP, Sagalowsky AI, **Schoenberg MP**, Lotan Y, Kamat A. Evidence-based gender related outcomes after radical cystectomy: results of a large multicenter study. Presented at the Annual American Urology Association Meeting in Chicago, IL, April, 2009.
60. Shariat SF, Svatek RS, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche H-M, Muller SC, Izawa JI, Isbarn H, Stief CG, Ficarra V, Lerner SP, Sagalowsky AI, **Schoenberg MP**, Kamat A, Dinney CP, Lotan Y, Fradet Y. Lymphovascular invasion is a powerful predictor of clinical outcomes on node-negative radical cystectomy patients: an international external validation study. Presented at the Annual American Urology Association Meeting in Chicago, IL April, 2009.

61. Guzzo TJ, Magheli A, Bivalacqua TJ, Nielsen ME, Attenello F, Ball MW, **Schoenberg MP**, Gonzalga ML. Pathologic upstaging at the time of radical cystectomy is associated with worse recurrence free survival in **patients with** BCG-refractory bladder cancer. Presented at the Annual American Urology Association Meeting in Chicago, IL, April, 2009.
62. “Cancer Incidence and Mortality among Workers Exposed to 3, 3-Dichlorobenzidine.” Presented at the 2010 AUA. San Francisco, CA. May 30, 2010.
63. Edwin Morales, Shahrokh Shariat, Pierre Karakiewicz, Bjorn Volkmer, Wassim Kassouf, Yves Fradet, Giacomo Novara, Hans-Martin Fritsche, Patrick Bastian, Jonathan Izawa, Christian Stief, Vincenzo Ficarra, Michael Rink, Seth Lerner, **Mark Schoenberg**, Colin Dinney, Eila Skinner, Yair Lotan, Arthur Sagalowsky, Robert Svatek. Moderated Poster. “Bladder Cancer: Metastatic Disease/Staging. 1906: Positive Surgical Margins Contribute to Delayed Failures in Patients Undergoing Radical Cystectomy for Bladder Cancer.” Presented at the 2012 AUA. Atlanta, GA. May 22, 2012.
64. Badrinath Konety, Gary Steinberg and **Mark Schoenberg**. “Muscle-invasive bladder cancer in the elderly.” Plenary Presentation, Presented at the 2013 AUA. San Diego, CA. May 7, 2013.
65. Nilda Gonzalez-Roibon, Jenny Kim, Alcides Chaux, Enrico Munari, Sheila Faraj, Carla Ellis, Rajni Sharma, Trinity Bivalacqua, **Mark Schoenberg**, Michael Carducci, George Netto: Overexpression of IGF1R Predicts Outcome in Invasive Urothelial Carcinoma of Urinary Bladder. Presented at the 2013 AUA. San Diego, CA. May 7, 2013. (Abstract #1429), 2013.
66. Michael Gorin, Max Kates, Jeffrey Mullins, Phillip Pierorazio, Deborah Kaye, Brian Matlaga, **Mark Schoenberg**, Trinity Bivalacqua: Impact of Surgical Volume on Perioperative Outcomes and Costs of Radical Cystectomy: Analysis of the Maryland Health Services Cost Review Commission Database. Presented at the 2013 AUA. San Diego, CA. May 7, 2013. (Abstract #1629), 2013.
67. Adrian Fairey, Eila Skinner, Stephen Boorjian, Jeffrey Wang, Igor Frank, **Mark Schoenberg**, Eric Hyndman, Adam Reese, Gary Steinberg, Michael Large, Christina Hulsbergen-vandeKaa, Max Bruins, Jie Cai, Siamak Daneshmand: Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy: a multi-institutional analysis. Presented at the 2013 AUA. San Diego, CA. May 7, 2013. (Abstract #1768), 2013.
68. Adam Reese, Mark Ball, Trinity Bivalacqua, George Netto, **Mark Schoenberg**: A Post-Chemotherapy Restaging Evaluation Improves the Correlation of Clinical

and Pathological Stage in Patients Treated with Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer. Presented at the 2013 AUA. San Diego, CA. May 7, 2013. (Abstract #1876), 2013.

XIII. INVITED LECTURES

1. **Schoenberg M** and Hanks G: Treatment decision-making and outcome of prostate cancer. Radiological Society of North America, Chicago, IL, November, 1995
2. **Schoenberg M**: The management of invasive and advanced bladder carcinoma. Presented at the American Urological Association Mid-Atlantic Section Seminar, March 29-31, 1996.
3. Marshall FF and **Schoenberg MP**: Cystectomy (male and female) in the management of invasive bladder cancer. Presented at the American Urological Association Annual Meeting in Orlando, FL, May 8, 1996.
4. **Schoenberg M**: Molecular diagnosis of bladder cancer and a molecular progression model for bladder carcinoma. Presented at the Charité-Symposium Urologie, in Berlin, Germany, November 29-30, 1996.
5. Marshall FF and **Schoenberg MP**: Cystectomy (male and female) in the management of invasive bladder cancer. Presented at the American Urological Association Annual Meeting in New Orleans, LA, April 16, 1997.
6. **Schoenberg MP**: International Workshop on Diagnostic and Prognostic Markers in Bladder Cancer, Barcelona, Spain, May 4-7, 1997.
7. **Schoenberg M**: Managing invasive and advanced bladder carcinoma. Presented at Nassau Surgical Society, Urology Section/GU Oncology, 34th Annual Meeting Long Island, NY December 10, 1997.
8. Visiting Professor at Einstein Medical Center/Philadelphia College of
a. Osteopathic Medicine, February 17-18, 1998.
9. **Schoenberg MP**: Management of invasive and advanced bladder cancer & alternate methods of urinary diversion. Presented at the American Urological Association Review Course, Dallas, TX, March 7, 1998.
10. Marshall FF and **Schoenberg MP**: Cystectomy (male and female) in the management of invasive bladder cancer. Presented at the American Urological Association Annual Meeting in San Diego, CA, May 30-June 4, 1998.
11. Visiting Professor at Stanford University Medical Center, July 16, 1998.

12. Visiting Professor at the University of Arizona, December, 1998.
13. Marshall FF and **Schoenberg MP**: Cystectomy and the management of muscle invasive bladder cancer. Presented at the American Urological Association Annual Meeting in Dallas, TX, May, 1999.
14. Marshall FF and **Schoenberg MP**: Cystectomy and the management of muscle invasive bladder cancer. Presented at the American Urological Association Annual Meeting in Atlanta, Georgia, May, 2000.
15. Clinical significance of premalignant alterations in the genitourinary tract. WHO Collaborative Project and Consensus Conference, Stockholm, Sweden, June, 2000.
16. Continent Diversion. Presented at the 58th Annual Meeting of the American Urological Association, October 15-18, 2000.
17. Molecular diagnostics for bladder cancer: Who let the dogs out? Presented at the International Bladder Symposium, Washington, DC, March, 2001.
18. Evaluation of hematuria. Presented at the Philip A. Tumulty Topics in Clinical Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, May 9, 2001.
19. Visiting Professor, University of Nijmegen, The Netherlands, May 16-19, 2001.
20. Marshall FF and **Schoenberg MP**: Cystectomy and the management of muscle invasive bladder cancer. Presented at the American Urological Association Annual Meeting in Anaheim, California, May, 2001.
21. Marshall FF and **Schoenberg MP**: Cystectomy and the management of muscle invasive bladder cancer. Presented at the American Urological Association Annual Meeting in Orlando, Florida, May, 2002.
22. Visiting Professor, University of Michigan, Ann Arbor, Michigan. "Uromythology: Bladder Cancer Detection and Treatment." November 6-7, 2002.
23. "Diagnosing Bladder and Prostate Cancer." Presented at Grand Rounds, North Arundel Hospital, Glen Burnie, MD September 18, 2003.
24. Visiting Professor, NYU Medical Center, New York, NY. "Uromythology of Bladder Cancer." November 4-5, 2003.
25. "Bladder cancer." Presented at the American Council of Life Insurers, Medical Section Annual Meeting, Baltimore, MD. June 27, 2004.

26. Visiting Professor, Wake Forest University Health Sciences, Winston-Salem, NC. April 5 - 6, 2006.
27. Visiting Professor, University of California San Diego, October 16-17, 2006.
28. "Update of Nerve Sparing Radical Cystoprostatectomy Outcomes." Presented at the Society of Urologic Oncology Meeting, National Institutes of Health, Bethesda, MD. December 1, 2006.
29. Visiting Professor, University of Rochester Medical Center, Rochester, NY. October 23-24, 2007.
30. Visiting Professor, The Cleveland Clinic, Cleveland, OH. November 6-7, 2007.
31. Visiting Professor, McGill University, Montreal, CA. October 28, 2008.
32. ESOU/Oncology Meeting, Lecturer, Istanbul, Turkey. January 17-18, 2009.
33. Guest Lecturer, FAUA Meeting, Ho Chi Minh City, Vietnam. June, 2009.
34. Guest Speaker, Case Western Reserve. July, 2009.
35. Visiting Professor, NYU, New York, NY. December 10-11, 2010.
36. Guest Lecturer, Lake Louise, Canada. March 4-5, 2011.

XIV. AUDIOTAPE/VIDEOTAPE

1. Carpiniello VL and **Schoenberg MP**: Management of condyloma acuminata. Medical Outlook for Urologists (audiotape) Vol. 4, No. 3, 1990.
2. Marshall FF, Brooks JC and **Schoenberg MP**: Technique of partial nephrectomy. (Videotape) American Urological Association Meeting, San Francisco, CA, May 14-19, 1994. *J Urol* **151**:202A (Abstract #V-9), 1994.

3) (in person: The Prime Minister will make a personal appearance.) en persona. 4) ((making remarks which are) insulting, especially about a person's appearance etc: personal remarks; Don't be personal!) indiscreto, maleducado, ofensivo. personal adj. 1. personal. a personal opinion una opinión personal. 2. personal / privado. a personal letter una carta personal. personal adjetivo personal; —Š objetos de uso personal personal effects. Part or all of this entry has been imported from the 1913 edition of Webster's Dictionary, which is now free of copyright and hence in the public domain. The imported definitions may be significantly out of date, and any more recent senses may be completely missing.(See the entry for personal in Webster's Revised Unabridged Dictionary, G. & C. Merriam, 1913.) personall (obsolete).